Pasithea Therapeutics Corp.
Pasithea Therapeutics is a clinical-stage biotechnology company focused on discovering, researching and developing treatments for RASopathies, MAPK pathway-driven tumors and other diseases, including central nervous system disorders. Its pipeline includes two therapeutic product candidates. The lead candidate, PAS-004, is an oral small-molecule MEK 1/2 inhibitor being studied for conditions including neurofibromatosis type 1 and advanced cancers. Pasithea is conducting clinical trials of PAS-004 in adults with advanced tumors and in adults with symptomatic, inoperable, incompletely resected or recurrent NF1-associated plexiform neurofibromas. Its early-stage PAS-001 program targets C4A for potential schizophrenia treatment. Pasithea ceased further development of PAS-003 for ALS during 2025. The company is headquartered in Miami Beach, Florida.
No SEC Form 4 filings for $KTTA in the last 30 days.
See all $KTTA insider activity →HC Wainwright & Co. maintained its Buy rating on Pasithea Therapeutics and raised its price target to $4 from $3, a 33.3% increase. The new target implies a 669.4% upside from the Nov 12 close of $0.52, according to the firm.
Pasithea Therapeutics (KTTA) reported positive Phase 1/1b trial results for PAS-004 in neurofibromatosis type 1. All participants showed tumor reductions, with median reductions of 41% and 46% across all and Phase 2 doses, respectively. No serious adverse events were reported. The FDA cleared a Phase 2 trial for PAS-004.
Pasithea Therapeutics (KTTA) received FDA clearance for a Phase 2 trial of PAS-004 in NF1 skin tumors. The study is placebo-controlled and will evaluate the oral MEK inhibitor. No FDA-approved systemic treatments exist for this condition, and Pasithea estimates 80,000 U.S. patients have moderate to severe cases.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning KTTA (Pasithea Therapeutics Corp.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent KTTA coverage spans financial news, regulation and technology.
HC Wainwright & Co. maintained its Buy rating on Pasithea Therapeutics and raised its price target to $4 from $3, a 33.3% increase. The new target implies a 669.4% upside from the Nov 12 close of $0.52, according to the firm.
Positive early‑stage data may lift sentiment and attract speculative buying.
The IND clearance removes a regulatory hurdle, likely boosting investor confidence and prompting short-term buying pressure.
Positive early‑stage data may lift sentiment and support a price uptick, but limited patient numbers keep impact modest.
Potential dilution and share price adjustment from the approved reverse split; governance changes may affect future strategy.
AlphAI scores every news story that mentions KTTA with an AI model for sentiment and relevance, and aggregates insider trades from Pasithea Therapeutics Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
HC Wainwright & Co. maintained its Buy rating on Pasithea Therapeutics and raised its price target to $4 from $3, a 33.3% increase. The new target implies a 669.4% upside from the Nov 12 close of $0.52, according to the firm.
Pasithea Therapeutics (KTTA) reported positive Phase 1/1b trial results for PAS-004 in neurofibromatosis type 1. All participants showed tumor reductions, with median reductions of 41% and 46% across all and Phase 2 doses, respectively. No serious adverse events were reported. The FDA cleared a Phase 2 trial for PAS-004.
Pasithea Therapeutics (KTTA) received FDA clearance for a Phase 2 trial of PAS-004 in NF1 skin tumors. The study is placebo-controlled and will evaluate the oral MEK inhibitor. No FDA-approved systemic treatments exist for this condition, and Pasithea estimates 80,000 U.S. patients have moderate to severe cases.
Pasithea reported Phase 1 data for PAS-004, showing stable disease in 4 advanced cancer patients, with no serious adverse events. The company noted no dose-limiting toxicities and supports daily dosing. The data is preliminary and requires further Phase 2 studies for validation.
Pasithea Therapeutics Corp. (KTTA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 9, 2026, the Company held its Annual Meeting. The stockholders of the Company acted upon the following three proposals at the Annual Meeting: (1) the election of two Class III directors; (2) the ratifica
Pasithea Therapeutics Corp. (KTTA) disclosed in an SEC Schedule 13G/A that Vivo Opportunity entities hold just under 10% of its common stock. Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P. each report 9.99% beneficial ownership, including common shares and pre-funded warrants. The filing cites 33,414,448 shares outstanding as of May 13, 2026.
Coastlands Capital LP purchased 100,000 indirectly-held shares of Pasithea Therapeutics Corp. (KTTA) at $0.53 on 2026-06-17.
Pasithea Therapeutics (KTTA) said the U.S. FDA granted Orphan Drug Designation to PAS-004 for amyotrophic lateral sclerosis (ALS). The company said PAS-004 is a macrocyclic MEK inhibitor and is in Phase 1 trials in advanced cancer and Phase 1/1b trials in NF1-associated plexiform neurofibromas. Orphan status can bring tax credits, fee exemptions, and up to seven years’ exclusivity after approval.
This page provides a comprehensive resource for investors and traders to access Pasithea Therapeutics (KTTA) SEC filings, including annual, quarterly, and material event reports, alongside insider trading forms. Each filing is accompanied by an AI-generated summary, sentiment and impact scores, and end-of-day stock performance data. The platform aims to simplify access to critical regulatory disclosures with analytical insights and historical market reactions.
MIAMI, Nov. 28, 2025 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp. ( "Pasithea" or the "Company" ) ( Nasdaq: KTTA. KTTAW ) , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associated ...
